Author:
Ramos-Casals Manuel,Brahmer Julie R.,Callahan Margaret K.,Flores-Chávez Alejandra,Keegan Niamh,Khamashta Munther A.,Lambotte Olivier,Mariette Xavier,Prat Aleix,Suárez-Almazor Maria E.
Publisher
Springer Science and Business Media LLC
Reference262 articles.
1. Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313–326 (2018).
2. Hoos, A. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235–247 (2016).
3. Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018). One of the first central reviews surveying the irAEs associated with ICIs and their management.
4. Ramos-Casals, M. et al. Immune-related adverse events induced by cancer immunotherapies. Big data analysis of 13,051 cases (Immunocancer International Registry). Ann. Rheum. Dis. 78, 607–608 (2019).
5. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). NCI https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (2019).
Cited by
837 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献